ストックスクリーナーアプリを入手
46.99
1.71%
0.79
前日終値:
$46.20
開ける：
$46.19
24時間の取引高:
579.31K
Relative Volume:
0.83
時価総額：
$3.36B
収益：
$58.89M
当期純損益:
$-240.88M
株価収益率:
-15.16
EPS:
-3.1
ネットキャッシュフロー:
$-239.96M
1週間 パフォーマンス:
+8.00%
1か月 パフォーマンス:
+17.86%
6か月 パフォーマンス:
+33.87%
1年 パフォーマンス:
+5.08%
1日の値動き範囲:
$45.84
$47.34
1週間の範囲:
$42.22
$47.34
52週間の値動き範囲:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
46.99 | 3.11B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-20 | 再開されました | Stifel | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera Therapeutics, Inc. $KYMR Shares Bought by Siren L.L.C. - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of "Buy" from Analysts - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Cinctive Capital Management LP - MarketBeat
Northern Trust Corp Reduces Stock Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Checkpoint Capital L.P. Acquires 59,070 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Trading Up 5.7%Here's What Happened - MarketBeat
Eventide Asset Management LLC Has $14.37 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Walleye Capital LLC Buys Shares of 10,059 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Published on: 2025-09-08 14:53:27 - beatles.ru
Kymera Therapeutics, Inc. $KYMR Holdings Lowered by Redmile Group LLC - MarketBeat
Why Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories? - Insider Monkey
Is Kymera Therapeutics Inc. reversing from oversold territoryDay Trade & Safe Capital Preservation Plans - Newser
Will Kymera Therapeutics Inc. outperform tech stocksJuly 2025 Reactions & Community Consensus Trade Signals - 뉴스영
Signal strength of Kymera Therapeutics Inc. stock in tech scannersWeekly Investment Report & Growth Focused Stock Reports - Newser
What is the PEG ratio of Kymera Therapeutics Inc.July 2025 WrapUp & Growth Focused Stock Reports - خودرو بانک
Is Kymera Therapeutics Inc. forming a breakout patternJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - خودرو بانک
Invesco Ltd. Buys 11,343 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Inc. stock trendline breakdownPortfolio Value Report & Stock Portfolio Risk Control - Newser
Institutional scanner results for Kymera Therapeutics Inc.Earnings Growth Summary & Stock Portfolio Risk Control - Newser
What candlestick patterns are forming on Kymera Therapeutics Inc.July 2025 Reactions & Consistent Income Trade Recommendations - Newser
Is Kymera Therapeutics Inc. stock poised for growth2025 Bull vs Bear & Daily Entry Point Trade Alerts - Newser
Will Kymera Therapeutics Inc. stock recover after recent dropPortfolio Risk Report & Reliable Price Action Trade Plans - Newser
What institutional flow reveals about Kymera Therapeutics Inc.2025 Market Outlook & Real-Time Market Trend Scan - Newser
What’s the outlook for Kymera Therapeutics Inc.’s sectorMarket Rally & AI Powered Market Entry Strategies - خودرو بانک
Can technical indicators confirm Kymera Therapeutics Inc.’s reversalQuarterly Profit Summary & Daily Volume Surge Signals - Newser
Should I trade or invest in Kymera Therapeutics Inc.2025 Risk Factors & Stepwise Trade Signal Guides - خودرو بانک
Kymera Therapeutics Announces New Chief Legal Officer - The Globe and Mail
Is Kymera Therapeutics Inc. a play on infrastructure spendingIndex Update & Real-Time Market Sentiment Alerts - خودرو بانک
Yiheng Capital Management L.P. Makes New $3.36 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Sentiment analysis tools applied to Kymera Therapeutics Inc.July 2025 Outlook & High Accuracy Trade Alerts - Newser
What Fibonacci levels say about Kymera Therapeutics Inc. reboundEarnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Real time social sentiment graph for Kymera Therapeutics Inc.July 2025 PostEarnings & High Return Trade Opportunity Guides - Newser
Will Kymera Therapeutics Inc. stock recover after earnings2025 Support & Resistance & Daily Stock Trend Reports - خودرو بانک
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary - citybiz
Kymera Therapeutics Presents at Citi's 2025 Biopharma Back to School Conference - AInvest
Kymera Names Adams Chief Legal Officer, Corporate Secretary - Bloomberg Law News
Kymera Therapeutics shares rise 2.08% intraday after appointing Brian Adams as Chief Legal Officer. - AInvest
Former Relay Therapeutics CLO Brian Adams Joins Immunology Pioneer Kymera as Legal Chief and Secretary - Stock Titan
Chart overlay techniques for tracking Kymera Therapeutics Inc.Quarterly Trade Review & AI Driven Stock Movement Reports - Newser
Aug Movers: Can Kymera Therapeutics Inc. keep up with sector leaders2025 Market Trends & Short-Term High Return Ideas - خودرو بانک
Kymera Therapeutics Inc. stock outlook for YEAR2025 Retail Activity & Reliable Trade Execution Plans - Newser
How sensitive is Kymera Therapeutics Inc. to inflation2025 Market Trends & Low Risk Growth Stock Ideas - خودرو بانک
Real time breakdown of Kymera Therapeutics Inc. stock performanceTrade Entry Report & Low Drawdown Momentum Trade Ideas - Newser
Visual trend scoring systems applied to Kymera Therapeutics Inc.2025 Momentum Check & Verified High Yield Trade Plans - Newser
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary | KYMR Stock News - GuruFocus
Market Fear: What’s the outlook for Kymera Therapeutics Inc.’s sectorTrade Exit Report & Fast Exit/Entry Strategy Plans - خودرو بانک
Trendlines Suggest Kymera Therapeutics Inc. May Bottom Out SoonVolume Spike & Weekly Breakout Opportunity Watchlist - beatles.ru
How liquid is Kymera Therapeutics Inc. stockJuly 2025 Patterns & AI Powered Trade Plan Recommendations - خودرو بانک
Using data models to predict Kymera Therapeutics Inc. stock movementRecession Risk & Low Risk Entry Point Tips - Newser
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
0.10%
大文字化:
|
ボリューム (24 時間):